Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

This is a randomized, double-blind, placebo-controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of Toripalimab injection (JS001) combined with platinum-based doublet drug chemotherapy versus placebo combined with platinum-based doublet drug chemotherapy for subjects with resectable, stage II-III NSCLC.

NCT Number	NCT04158440
Lead Sponsor	Shanghai Junshi Bioscience Co., Ltd.
Conditions	Stage II-III Non-small Cell Lung Cancer
Enrollment	501 participants
Start Date	2020-04-07
Primary Completion	2026-04-18 (estimated)
Study Completion	2026-07-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-23